Early breast cancer: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up

The challenge of avoiding over- and under-treatment in older women with ductal cancer in situ: A scoping review of existing knowledge gaps and a meta-analysis of real-world practice patterns

“…Available national and international guidelines do not routinely advise screening in women older than 75 years of age. Most screening programmes extend to the age of 70 [16,17]. In some lands, such as Sweden and the Netherlands screening extends to 74 to75 years [18][19][20].…”

Myocardial dysfunction in breast cancer survivors: ‘you can observe a lot by just watching’

“…They are highly effective chemotherapeutic agents that possess marked antitumour activity, but also are hampered by significant off‐target toxicities . Despite recent advances in sophisticated molecularly targeted and immune‐mediated oncologic therapies, anthracyclines continue to play a prominent role in the management of less differentiated subtypes of breast cancer (BC), such as oestrogen receptor‐, progesterone receptor‐, and her2‐negative tumors . Off‐target cardiotoxicity leading to progressive cardiomyopathy and ultimately heart failure has plagued the utilization of anthracyclines since the inception of their clinical application .…”

Toxicity and Pharmacogenomic Biomarkers in Breast Cancer Chemotherapy

“…Indeed, it is the backbone of systemic therapy in metastatic BC, and indispensable in many subtypes of early BC; specifically, for luminal B, Her-2 enriched, and triple-negative cases. Nevertheless, some cases of early luminal A (ER-positive and HER-2 negative) with high tumor burden (e.g., three or more lymph nodes are involved) benefit from chemotherapy (Twelves et al, 2016;Cardoso et al, 2019). The main chemotherapy classes used are anthracyclines, anti-microtubules (taxanes), alkylating agents (cyclophosphamide), antimetabolites (5-fluorouracil, capecitabine), platinum compounds (cisplatin), and others.…”